← All trials
NCT03183245
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 29, 2017
- Primary completion
- Apr 22, 2024
- Completion date
- Sep 30, 2025
- First posted
- Jun 12, 2017
- Last posted
- Nov 18, 2024
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Humacyte, Inc.Lead sponsor
- California Institute for Regenerative Medicine (CIRM)Collaborator
- CTI Clinical Trial and Consulting ServicesCollaborator
- Humacyte, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.